A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT ID: NCT00261443

Last Updated: 2023-04-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical research study is to learn if outpatients with bipolar mania who are partially nonresponsive to lithium or valproate monotherapy can achieve stable symptoms on a combination treatment of aripiprazole plus lithium or valproate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A1

/Active Comparator

Group Type PLACEBO_COMPARATOR

Lithium or Valproate with placebo (PBO)

Intervention Type DRUG

Tablets, Oral, once daily

lithium 250-2100 mg/day

valproate 250-2500mg/day

Placebo once daily

A2

Group Type EXPERIMENTAL

Lithium or Valproate with Aripiprazole

Intervention Type DRUG

Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)

lithium 250-2100 mg/day

valproate 250-2500mg/day

aripiprazole 15-30 mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lithium or Valproate with placebo (PBO)

Tablets, Oral, once daily

lithium 250-2100 mg/day

valproate 250-2500mg/day

Placebo once daily

Intervention Type DRUG

Lithium or Valproate with Aripiprazole

Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)

lithium 250-2100 mg/day

valproate 250-2500mg/day

aripiprazole 15-30 mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Abilify BMS-337039

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women \> or = to 18 years of age meeting Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, currently experiencing a manic or mixed episode with a history of one or more manic or mixed episodes or sufficient severity to require hospitalization and/or treatment with a mood stabilizer or antipsychotic.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tuscaloosa Va Medical Center

Tuscaloosa, Alabama, United States

Site Status

Pravin Kansagra, M.D.

Anaheim, California, United States

Site Status

Psychopharmacology Research Network Of Torrance

Cerritos, California, United States

Site Status

Atp Clinical Research, Inc.

Costa Mesa, California, United States

Site Status

Us Clinical Research Centers, Llc

Costa Mesa, California, United States

Site Status

Va Long Beach Healthcare System

Long Beach, California, United States

Site Status

Synergy Clinical Research Center

National City, California, United States

Site Status

University Of California, Irvine Medical Center

Orange, California, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Orlando, Florida, United States

Site Status

University Of South Florida

Tampa, Florida, United States

Site Status

Carman Research

Smyrna, Georgia, United States

Site Status

University Of Massachusetts Medical School

Worcester, Massachusetts, United States

Site Status

Psych Care Consultants Research

St Louis, Missouri, United States

Site Status

Cns Research Institute, P.C.

Clementon, New Jersey, United States

Site Status

Neuropsychiatric Research Associates

New York, New York, United States

Site Status

Behavioral Medical Research Of Staten Island

Staten Island, New York, United States

Site Status

Richmond Behavioral Associates

Staten Island, New York, United States

Site Status

Psychiatry And Clinical Research

Raleigh, North Carolina, United States

Site Status

Rakesh Ranjan, Md & Associates, Inc.

Beachwood, Ohio, United States

Site Status

University Of Cincinnati Medical Center

Cincinnati, Ohio, United States

Site Status

Metro Health Medical Center

Cleveland, Ohio, United States

Site Status

Midwest Clinical Research Center

Dayton, Ohio, United States

Site Status

Portland Va Medical Center

Portland, Oregon, United States

Site Status

Senior Adults Specialty Research, Inc.

Austin, Texas, United States

Site Status

Futuresearch Trials

Dallas, Texas, United States

Site Status

Insite Clinical Research

DeSoto, Texas, United States

Site Status

Red Oak Psychiatry Associates, Pa

Houston, Texas, United States

Site Status

University Of Utah School Of Medicine

Salt Lake City, Utah, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

Local Institution

Salvador, Estado de Bahia, Brazil

Site Status

Local Institution

Aparecida de Goinia, Goiás, Brazil

Site Status

Local Institution

Pelotas, Rio Grande do Sul, Brazil

Site Status

Local Institution

Rio de Janeiro, , Brazil

Site Status

Local Institution

São Paulo, , Brazil

Site Status

Local Institution

São Paulo, , Brazil

Site Status

Local Institution

Burgas, , Bulgaria

Site Status

Local Institution

Rousse, , Bulgaria

Site Status

Local Institution

Rijeka, , Croatia

Site Status

Local Institution

Split, , Croatia

Site Status

Local Institution

Zadar, , Croatia

Site Status

Local Institution

Zagreb, , Croatia

Site Status

Local Institution

Brno, , Czechia

Site Status

Local Institution

Brno, , Czechia

Site Status

Local Institution

Havířov, , Czechia

Site Status

Local Institution

Litoměřice, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Přerov, , Czechia

Site Status

Local Institution

Nantes, Cedex 01, France

Site Status

Local Institution

Dole, , France

Site Status

Local Institution

Hénin-Beaumont, , France

Site Status

Local Institution

Jonzac, , France

Site Status

Local Institution

La Seyne-sur-Mer, , France

Site Status

Local Institution

Marseille, , France

Site Status

Local Institution

Nantes, , France

Site Status

Local Institution

Nîmes, , France

Site Status

Local Institution

Rennes, , France

Site Status

Local Institution

Hyderabad, Andhra Pradesh, India

Site Status

Local Institution

Ahmedabad, Gujarat, India

Site Status

Local Institution

Ahmedabad, Gujarat, India

Site Status

Local Institution

Kalyan (West), Maharashtra, India

Site Status

Local Institution

Nāgūr, Maharashtra, India

Site Status

Local Institution

Pune, Maharashtra, India

Site Status

Local Institution

Mangalore, Manipal, India

Site Status

Local Institution

Mumbai, Sion (W), India

Site Status

Local Institution

Delhi, , India

Site Status

Local Institution

Hyderabad, , India

Site Status

Local Institution

Mumbai, , India

Site Status

Local Institution

Mumbai, , India

Site Status

Local Institution

New Delhi, , India

Site Status

Local Institution

New Delhi, , India

Site Status

Local Institution

Izhevsk, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Nizhny Novgorod, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saratov, , Russia

Site Status

Local Institution

Tomsk, , Russia

Site Status

Local Institution

Pretoria, Gauteng, South Africa

Site Status

Local Institution

Berea, KwaZulu-Natal, South Africa

Site Status

Local Institution

Durban, KwaZulu-Natal, South Africa

Site Status

Local Institution

Cape Town, Western Cape, South Africa

Site Status

Local Institution

Paarl, Western Cape, South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Brazil Bulgaria Croatia Czechia France India Russia South Africa

References

Explore related publications, articles, or registry entries linked to this study.

Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011 Mar;13(2):133-44. doi: 10.1111/j.1399-5618.2011.00898.x.

Reference Type DERIVED
PMID: 21443567 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CN138-189

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Aripiprazole in Patients With Acute Mania
NCT00095511 COMPLETED PHASE3